Indices Trade Lower; Metal Shares Shine For 2Nd Day

16-Apr-26   12:43 Hrs IST
The key domestic indices traded with modest losses in early afternoon trade despite positive global cues. Market participants are monitoring de-escalation situation between Iran and US. The Nifty traded below the 24,150 mark.

Metal shares witnessed buying demand for second consecutive trading session.

At 12:25 IST, the barometer index, the S&P BSE Sensex declined 333.61 points or 0.46% to 77,753.97. The Nifty 50 index fell 92 points or 0.37% to 24,144.10.

In the broader market, the BSE 150 MidCap Index shed 0.07% and the BSE 250 SmallCap Index rose 0.23%.

The market breadth was positive. On the BSE, 2,262 shares rose and 1,870 shares fell. A total of 204 shares were unchanged.

Derivatives:

The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, declined 0.81% to 18.52. The Nifty 28 April 2026 futures were trading at 24,181.50, at a premium of 31.50 points as compared with the spot at 24,150.

The Nifty option chain for the 28 April 2026 expiry showed a maximum call OI of 48.9 lakh contracts at the 25,000 strike price. A maximum put OI of 45.2 lakh contracts was seen at the 23,000 strike price.

Buzzing Index:

The Nifty Metal index jumped 1.46% to 12,730.95. The index rallied 3.26% in the two consecutive trading sessions.

Hindalco Industries (up 3.04%), Hindustan Zinc (up 2.81%), National Aluminium Company (up 2.42%), Vedanta (up 2.13%), Hindustan Copper (up 1.8%), Steel Authority of India (up 1.62%), Adani Enterprises (up 1.22%), Lloyds Metals & Energy (up 1.1%), Jindal Steel (up 0.96%) and Jindal Stainless (up 0.65%) surged.

Stocks in Spotlight:

John Cockerill India jumped 3.62% after the company received a contract form JSW Steel Coated Products to design Continuous Galvanizing Line (CGL#3) at Khopoli plant. The contract is valued at Rs 300 crore.

Alembic Pharmaceuticals advanced 2.05% after the company announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Methotrexate Injection USP.

Tejas Networks tumbled 4.25% after the company reported a net loss of Rs 211 crore in Q4 FY26 as against a net loss of Rs 72 crore in Q4 FY25. Net revenue fell 83% to Rs 333 crore in the March quarter from Rs 1,907 crore recorded in the same period last year.

Trade, Track, Thrive!

Experience insight with every swipe.

Open your Chola Securities account in minutes and start trading across stocks, derivatives, mutual funds, and more — all in one place.

Start Investing Now →
Trading App Screen
We are hiring! Check out open positions and send your CV to csecrecruit@chola.murugappa.com
Pre-Apply for IPOs
Chola Securities App
Install
🌐
Stay on Web